Additionally, we identified HDAC1/PKA signaling as a novel regulatory axis for Tph1 expression, thus providing a potential therapy for type 2 diabetes characterized by impaired β-cell functional compensation. The gene discussed is TPH1; the disease is type 2 diabetes mellitus.